Why Heidi Overton’s FDA Nomination Fell Apart Hours Before a Senate Vote
The Senate health committee was supposed to vote Wednesday morning on whether to advance Dr. Heidi Overton’s nomination to run the Food and Drug Administration. On Tuesday, Nov. 17, the White House pulled her name. By the end of the evening, the Republican who chaired that committee, Louisiana Sen. Bill Cassidy, was publicly saying he believed she could have been confirmed. Reuters was reporting, based on three people familiar with the matter, that the White House had concluded there wasn’t enough support.
That tension is the story. The withdrawal is confirmed. The precise reason the administration decided to walk away has been described differently by the people who were watching the votes and the senator who was supposed to run the meeting. If you saw a headline that made it sound like the Senate voted her down, the timeline is important. The White House withdrew the nomination before senators recorded how they would vote.

President Donald Trump nominated Overton in August, about three months after the resignation of former FDA Commissioner Marty Makary, Reuters reported. Overton is trained in preventive medicine and served as a deputy director of the White House Domestic Policy Council. She came into the nomination with experience inside Trump’s policy operation. That background also shaped questions about how she would handle a disagreement with the administration as head of a scientific and regulatory agency.
At her September confirmation hearing, senators pressed her about vaccines and abortion medication. Those questions involved separate decisions. On vaccines, Cassidy was particularly critical of her support for the administration’s proposal to separate components of combination shots such as MMR, which protects against measles, mumps and rubella. CBS News and Reuters also reported scrutiny over her position on mifepristone, an FDA-approved drug used in medication abortion.
This was a hearing about how a nominee would handle regulatory decisions. Senators were asking how she would weigh the views of the White House and the Department of Health and Human Services against the evidence and recommendations put in front of her by the FDA’s own staff. For an agency that makes decisions about products people use every day, that question matters after the politics of a nomination are over.
Republicans held 12 seats and Democrats held 11 on the Senate Health, Education, Labor and Pensions Committee. If Democrats opposed Overton as a group, the Republican majority had room for very little disagreement. Before the planned vote, Cassidy said he was undecided. The Associated Press reported that he had previously described her position on breaking up combination vaccines as close to disqualifying.
Later Tuesday, Cassidy said he believed she had enough support to clear the committee and the full Senate. He also suggested the decision came down to disagreements over commitments anti-abortion Republicans wanted from the White House. That was his account. Reuters’ sources described insufficient support in Congress, and CBS reported skepticism among some lawmakers and administration allies over more than one issue. Because the vote was canceled, readers never got a public roll call to compare with those accounts.
The timing matters for another reason. The committee vote would have been a step toward a floor vote. Even if she had advanced Wednesday, the full Senate still would have had to consider her for confirmation. In this case, the process ended in between the hearing and that first vote.
Reuters reported that Kyle Diamantas, the FDA’s deputy commissioner for food, was serving as acting commissioner. It also reported, citing people familiar with the discussions, that the White House was considering Kansas Republican Sen. Roger Marshall as a possible nominee. CBS reported that officials had been talking to potential candidates before withdrawing Overton. A report that someone is being considered is an early stage. A formal nomination and a scheduled hearing are the developments that would put a successor on the same Senate track.
For most of us, the FDA shows up in a more practical way than a confirmation fight. Think about a safety alert for a medical device, a question about a new prescription, or a recall notice for food already sitting in your kitchen. Those decisions come through an agency that has to explain what its staff found, what action it’s taking and what people should do next. It helps when the person leading the agency can answer all three questions clearly.
The next nominee should be asked for a specific example of how they would handle a decision when the political pressure is coming from one direction and the evidence points in another. That’s what I’d want to hear on the record. Overton’s withdrawal leaves the FDA under acting leadership and leaves senators with the same underlying questions they brought to her hearing.



Comments